Study identifier:D6970C00002
ClinicalTrials.gov identifier:NCT06034743
EudraCT identifier:N/A
CTIS identifier:EU CT 2023-505499-32
A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension
Uncontrolled Hypertension
Phase 3
No
Baxdrostat, Placebo
All
720
Interventional
18 Years - 130 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 2 mg baxdrostat 2 mg baxdrostat administered orally, once daily (QD). | Drug: Baxdrostat Baxdrostat tablet administered orally, once daily (QD). Unit dose strengths: • 1 mg per tablet for 1 mg baxdrostat Arm; • 2 mg per tablet for 2 mg baxdrostat Arm. Other Name: CIN-107 |
Experimental: 1 mg baxdrostat 1 mg baxdrostat administered orally, once daily (QD). | Drug: Baxdrostat Baxdrostat tablet administered orally, once daily (QD). Unit dose strengths: • 1 mg per tablet for 1 mg baxdrostat Arm; • 2 mg per tablet for 2 mg baxdrostat Arm. Other Name: CIN-107 |
Placebo Comparator: Placebo Placebo administered orally, once daily (QD). | Drug: Placebo Placebo tablet matching baxdrostat, administered orally, once daily (QD). |